Mirae Asset Global Investments Co. Ltd. Has $930,000 Stock Holdings in Vericel Co. (NASDAQ:VCEL)

Mirae Asset Global Investments Co. Ltd. grew its holdings in Vericel Co. (NASDAQ:VCEL) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,115 shares of the biotechnology company’s stock after purchasing an additional 767 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of Vericel worth $930,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in VCEL. Envestnet Asset Management Inc. raised its stake in Vericel by 54.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 126,383 shares of the biotechnology company’s stock worth $4,236,000 after buying an additional 44,507 shares during the period. Legato Capital Management LLC raised its stake in Vericel by 20.6% during the 4th quarter. Legato Capital Management LLC now owns 10,340 shares of the biotechnology company’s stock worth $368,000 after buying an additional 1,765 shares during the period. Federated Hermes Inc. raised its stake in Vericel by 6.5% during the 3rd quarter. Federated Hermes Inc. now owns 462,467 shares of the biotechnology company’s stock worth $15,502,000 after buying an additional 28,262 shares during the period. Citigroup Inc. raised its stake in Vericel by 19.0% during the 3rd quarter. Citigroup Inc. now owns 71,271 shares of the biotechnology company’s stock worth $2,389,000 after buying an additional 11,402 shares during the period. Finally, FMR LLC raised its stake in Vericel by 39.5% during the 3rd quarter. FMR LLC now owns 571,298 shares of the biotechnology company’s stock worth $19,150,000 after buying an additional 161,652 shares during the period.

Insider Activity

In other news, Director Robert L. Md Zerbe sold 3,278 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total value of $169,046.46. Following the completion of the transaction, the director now directly owns 23,395 shares of the company’s stock, valued at $1,206,480.15. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Robert L. Md Zerbe sold 3,278 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total value of $169,046.46. Following the completion of the transaction, the director now directly owns 23,395 shares of the company’s stock, valued at $1,206,480.15. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $44.67, for a total value of $781,725.00. Following the transaction, the chief executive officer now directly owns 194,870 shares of the company’s stock, valued at $8,704,842.90. The disclosure for this sale can be found here. Insiders sold a total of 56,767 shares of company stock valued at $2,561,506 over the last three months. Corporate insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on VCEL. Truist Financial reaffirmed a “buy” rating and set a $54.00 price target on shares of Vericel in a research note on Tuesday, March 26th. TheStreet raised Vericel from a “d+” rating to a “c-” rating in a research note on Monday, January 29th. Finally, HC Wainwright upped their price target on Vericel from $46.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.40.

Vericel Stock Up 2.3 %

Shares of Vericel stock opened at $46.42 on Wednesday. The company has a market cap of $2.25 billion, a PE ratio of -515.78 and a beta of 1.71. Vericel Co. has a 52 week low of $29.24 and a 52 week high of $53.05. The business has a 50 day moving average price of $47.55 and a 200-day moving average price of $40.63.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.18 by $0.08. The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $64.28 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The company’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.12 earnings per share. As a group, research analysts anticipate that Vericel Co. will post 0.09 EPS for the current year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.